- Stock: In Stock
- Brand: Acme Laboratories Limited
- Product ID: Glimepiride
100% Secure Payment
Dactus 3 mg Tablet
Description
DACTUS (Glimepiride) is an oral hypoglycemic drug belonging to the sulphonylurea group. It stimulates the release of insulin from functioning pancreatic -cells. It also can increase sensitivity of peripheral tissues to insulin.
Composition
DACTUS 1 : Each tablet contains Glimepiride BP 1 mg.
DACTUS 2 : Each tablet contains Glimepiride BP 2 mg.
DACTUS 3 : Each tablet contains Glimepiride BP 3 mg.
Indications
DACTUS (Glimepiride) is indicated in type-2 diabetes mellitus when dietary modification has failed in adequate glycemic control.
Dosage and Administration
Usual Starting Dose:
The usual starting dose of DACTUS as initial therapy is 1-2 mg once daily, administered with breakfast or the first main meal. Those patients who may be more sensitive to hypoglycemic drugs should be started at
1 mg once daily. The maximum starting dose of DACTUS should be not more than 2 mg.
Usual Maintenance Dose:
The usual maintenance dose is 1 to 4 mg once daily. The maximum recommended dose is 8 mg once daily. After reaching a dose of 2 mg, dosage increases should be made in increments of not more than 2 mg at 1-2 week intervals based upon the patient’s blood glucose response.
OR AS DIRECTED BY THE PHYSICIAN.
Side Effects
Hypoglycemia, gastrointestinal disturbances such as nausea, vomiting, abdominal pain, diarrhea and constipation may occur.
Contraindications
DACTUS is contraindicated in patients with known hypersensitivity to the drug. It is also contraindicated in patients with type 1 diabetes mellitus, diabetic coma, and ketoacidosis.
Use in Pregnancy & Lactation
Pregnancy: Glimepiride is contraindicated during pregnancy. Lactation: Glimepiride must not be taken during lactation.
Use in Children & Elderly
Children: Safety and effectiveness in children have not been established.
Elderly: No overall differences in safety or effectiveness were observed between elderly and younger. There are no significant differences in pharmacokinetics between the elderly and adults.
Drug Interactions
1. The hypoglycemic action of Glimepiride may be potentiated by certain drugs, include NSAID and other drugs that are highly protein bound such as salicylates, sulfonamides, chloramphenicol, coumarin derivatives, probenecid, monoamine oxidase inhibitors, and beta adrenargic blocking agents.
2. Weakening of the blood sugar lowering effect of Glimepiride may occur with acetazolamide barbiturates, corticosteroids, diazoxide, diuretics, epinephrine and other sympathomimetic agents, laxatives, oestrogens and progestogens, phenothiazines, phenytoin, rifampicin and thyroid hormones. 3. H2 -receptors antagonists, clonidine and reserpine may lead to either potentiation or weakening of the blood sugar lowering effect.
Precautions
In the initial weeks of treatment, the risk of hypoglycemia may be increased. If such risk is present it may be necessary to adjust the dosage of Glimepiride.
Overdose
Overdosage of sulphonylureas, including Glimepiride can produce hypoglycemia. Severe hypoglycemic reactions with coma, or neurological impairments occur infrequently.
Supply
DACTUS 1: Each box contains 510 tablets in blister strips.
DACTUS 2: Each box contains 4 10 tablets in blister strips.
DACTUS 3: Each box contains 310 tablets in blister strips.